학술논문
Challenge in treating COVID‐19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels.
Document Type
Article
Author
Source
Subject
*PULMONARY aspergillosis
*VORICONAZOLE
*LIQUID chromatography-mass spectrometry
*
*
Language
ISSN
0306-5251
Abstract
There is a cumulative evidence suggesting COVID-19 victims are prone to COVID-19 associated pulmonary aspergillosis (CAPA). It was observed that COVID-19 patients were more prone to high voriconazole levels than non-COVID-19 patients. COVID-19 and non-COVID-19 patients were comparable in terms of gender (46.2% vs. 46.2%, I p i = 1.000), age [median (inter quartile range): 63 (51.5-69.5) vs. 66 (46.5-72.0) years, I p i = .960] and the number of comorbidities [median (inter quartile range): 2 (1-3.5) vs. 3 (1-4), I p i = .724]. [Extracted from the article]